In addition, the mammalian target of rapamycin (mTOR) is a downstream target of PI3K/Akt, and inhibition of mTOR by its inhibitor RAD001 (everolimus) potentiated the effects of ATRA to induce growth arrest and differentiation of human AML cell lines NB4 and HL-60 [40]. Here, AKT1 is linked to acute myeloid leukemia.